Ongoing developments in sporadic inclusion body myositis

Machado, Pedro M., Ahmed, Mhoriam, Brady, Stefen, Gang, Qiang, Healy, Estelle, Morrow, Jasper M., Wallace, Amanda C., Dewar, Liz, Ramdharry, Gita, Parton, Matthew, Holton, Janice L., Houlden, Henry, Greensmith, Linda and Hanna, Michael G. (2014) Ongoing developments in sporadic inclusion body myositis. Current Rheumatology Reports, 16(477), ISSN (print) 1523-3774


Sporadic inclusion body myositis (IBM) is an acquired muscle disorder associated with ageing, for which there is no effective treatment. Ongoing developments include: genetic studies that may provide insights regarding the pathogenesis of IBM, improved histopathological markers, the description of a new IBM autoantibody, scrutiny of the diagnostic utility of clinical features and biomarkers, the refinement of diagnostic criteria, the emerging use of MRI as a diagnostic and monitoring tool, and new pathogenic insights that have led to novel therapeutic approaches being trialled for IBM, including treatments with the objective of restoring protein homeostasis and myostatin blockers. The effect of exercise in IBM continues to be investigated. However, despite these ongoing developments, the aetiopathogenesis of IBM remains uncertain. A translational and multidisciplinary collaborative approach is critical to improve the diagnosis, treatment, and care of patients with IBM.

Actions (Repository Editors)

Item Control Page Item Control Page